Tonix Pharmaceuticals Presents Data on TNX-801 Mpox Vaccine
Tonix Pharmaceuticals Holding Corp! presented data on TNX-801, a live virus vaccine investigational candidate, at the World Vaccine Congress–Europe 2025.
TNX-801 is designed to provide durable protection against mpox and smallpox. It demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models.
Data supports the advancement of TNX-801 toward clinical development. A copy of the presentation is available on the Tonix website at www.tonixpharma.com.
Titled “Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine”
Author's summary: Tonix Pharmaceuticals presents data on TNX-801 vaccine.
More News
- Argentina to move Israel embassy to Jerusalem by spring 2026
- Costumes pour homme Strellson
- Experimenting with Houdini for Dog Grooming
- What Philip Roth taught me about my life as a Jewish man
- ‘Dancing With the Stars’ Costume Designer Daniela Gschwendtner Shares Show Secrets
- Costumes et tenues de danse pour tous les styles
- When does Hanukkah 2025 start? Date, foods, traditions for Jewish holiday
- God Is Preparing a Place for You: The Promise of Jesus’ Return and Eternal Home
- The Jerusalem Post marks 93 years as a link to Israel and the Jewish world
- An engineering feat: the 26-year-old Australian making costumes for Lady Gaga